Fundraising Fox

Titan Pharmaceuticals

San Francisco, US · Delaware corporation · 1 known investors

Biotech

Founders & leadership

DH
Dane HallbergExecutive
KB
Katherine BeebeExecutive
SB
Sunil BhonsleExecutive
MR
Marc RubinExecutive
JA
Joseph A. AkersNamed on SEC filing
RK
Rajinder KumarNamed on SEC filing
JR
James R. McNab, Jr.Named on SEC filing
SA
Scott A. SmithNamed on SEC filing
MD
M. David McFarlaneNamed on SEC filing

Investors · 1

Also in the syndicate · 1

Blue Harbour Asset Management

Funding

SEC filings, press & company announcements

$15.5M disclosed across 4 of 6 rounds · 2019–2025

  • Undisclosed amountSeries C Convertible Preferred StockJun 2025

    Blue Harbour Asset Management

    Source ↗
  • Undisclosed amountSeries B Convertible Preferred StockApr 2025

    Blue Harbour Asset Management

    Source ↗
▶$1.5MraisedFeb 2022 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Katherine Beebe DeVarneyExecutive Officer, Director
  • James R. McNab, Jr.Director
  • Marc RubinExecutive Officer, Director
  • Joseph A. AkersDirector
  • M. David McFarlaneDirector
Offering amount
$7M
Amount sold
$1.5M
Sales commissions
$106.4K
Placement agents
Maxim Group LLC
First sale
Feb 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.7MraisedJan 2021 · 7 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph A. AkersDirector
  • Katherine Beebe DeVarneyExecutive Officer, Director
  • M. David McFarlaneDirector
  • Marc RubinExecutive Officer
  • James R. McNab, Jr.Director
Offering amount
$9.7M
Amount sold
$9.7M
Finders' fees
$677.2K
First sale
Jan 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedJan 2020 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Marc RubinExecutive Officer, Director
  • Sunil BhonsleExecutive Officer, Director
  • Katherine DeVarneyExecutive Officer, Director
  • Scott A. SmithDirector
  • Joseph A. AkersDirector
  • M. David McFarlaneDirector
  • James R. McNab, Jr.Director
  • Dane HallbergExecutive Officer
Offering amount
$2.2M
Amount sold
$2.2M
Finders' fees
$152.3K
First sale
Jan 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.1MraisedAug 2019 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph A. AkersDirector
  • Rajinder KumarDirector
  • James R. McNab, Jr.Director
  • Scott A. SmithDirector
  • Dane HallbergExecutive Officer
  • Katherine BeebeExecutive Officer
  • Sunil BhonsleExecutive Officer, Director
  • Marc RubinExecutive Officer, Director
  • M. David McFarlaneDirector
Offering amount
$2.1M
Amount sold
$2.1M
Finders' fees
$148.8K
First sale
Aug 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Titan Pharmaceuticals completes merger, shares to cease trading on Nasdaq By Investing.cominvesting.com · Oct 2025Titan Pharmaceuticals Raises $600,000 Through Convertible Preferred Stock at $3.40 Conversion Pricestocktitan.net · Jun 2025Titan Pharmaceuticals Secures $1M Strategic Investment From Blue Harbour | TTNP Stock Newsstocktitan.net · Apr 2025Buy Titan Pharma Stock – TTNP Stock Quote Today & Investment Insights - Public.compublic.com

Frequently asked questions

How much funding has Titan Pharmaceuticals raised?
Titan Pharmaceuticals has disclosed $15.5M raised across 4 of its 6 known rounds.
Where is Titan Pharmaceuticals headquartered?
Titan Pharmaceuticals is headquartered in San Francisco, US.